Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Placebo Controlled, Prospective, Multicenter Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

NCT02968368 is registered in ClinicalTrials.gov with Shield Therapeutics as lead sponsor.

NCT NCT02968368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02968368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Placebo Controlled, Prospective, Multicenter Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease
Lead sponsor
Shield Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
December 1, 2016
Completion date
October 10, 2018
Enrollment
167 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

iron-deficiency anemia, renal insufficiency, chronic